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Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition which can lead
to comorbidities of variable severity, cognitive dysfunction included. The role of supplemental oxygen in preventing
COPD-induced cognitive deterioration is still debated, but only episodically investigated. The aim of this study was
to compare the cognitive pattern of hypoxemic COPD subjects treated with long-term oxygen (LTOT) to that of
patients of comparable severity assuming oxygen on irregular basis, and to normal reference values.
Methods: Lung function, arterial blood gases, health status, and cognitive function measured by means of four
psychometric tests focusing different domains of cognition (such as: MMSE, Clock test; TMT-A; TMT-B) were assessed
in 146 well matched hypoxemic COPD patients (males n = 96, 66%; mean age = 70.5 ± 12.9). Seventy-three patients
were assuming long-term oxygen (LTOT), while the remaining seventy-three were only using oxygen as needed
(AN). Regarding statistics, t test and ANOVA (Duncan test) were used to analyze data, assuming a p < 0.05 as the
lowest limit of significance.
Results: Even though all COPD patients showed a poorer psychometric profile vs corresponding normal reference
values, LTOT patients showed a lower prevalence of severe deterioration in cognition. Also the extent of
impairment was significantly lower in these patients when assessed by TMT-A and TMT-B (p < 0.012 and 0.001,
respectively), but not when measured by MMSE and Clock test (both p = ns). Several domains of cognition are
variably affected by persistent hypoxemia in COPD patients. A panel of psychometric tools is needed for identifying
the pattern of cognitive dysfunctions in these patients. Memory and attention (functions assessed by MMSE and
Clock test) are only mildly-moderately affected, while visual processing, reproduction of numeric sequences,
cognition flexibility, and shifting capacity (functions assessed by TMT-A and TMT-B) are much more deteriorated
(p < 0.012 and p < 0.001, respectively).
Conclusions: Only LTOT allows to preserve significantly (p < 0.022) cognitive functions from the COPD-induced
deterioration. This assumption is of strategic value for COPD patients who are prescribed long-term oxygen because
they frequently are not aware of the cognitive risks related to their condition.
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Chronic Obstructive Pulmonary Disease (COPD) is a
pathological condition of respiratory system prevailing since
the 5th decade of life and characterized by a high socio-
economic impact [1-3]. COPD can progressively affect the
function of other organs (e.g. heart, vasculature, muscles,
kidney, liver, gastro-enteric apparatus, and brain) leading to
comorbidities of different severity [4,5].
Impairment of cognitive functions is one of the effects
of comorbidities related to COPD [6-9]. It has long been
associated with severe pulmonary dysfunction [10-15],
even if at a changing prevalence in different studies, be-
cause depending on the methods for assessing cognition
and on the consistency of subjects’ sample [16-20]. At
present, some authors affirm that the lung function impair-
ment assessed by means of FEV1 can be associated to a
progressive cognitive function impairment in later life [15].
It has been demonstrated that hypoxemia per se can play a
role in affecting cognition [21], and it might contribute to
the onset and the progressive worsening of cognitive func-
tions in subjects suffering from COPD, particularly in most
severe cases [22]. Neverheless, other authors support
the hypothesis that cognitive function is only mildly im-
paired without hypoxemia, and that cognitive dysfunc-
tion is higher in hypoxemic patients [9].
On the other hand, the role of supplemental oxygen in
preventing the impairment of COPD-induced cognitive
dysfunction is still debated.
Aim of the present study was to compare the cognitive
dysfunction assessed in hypoxemic COPD subjects man-
aged according to a strict protocol of home long-term
oxygen (LTOT) to that of patients of comparable sever-
ity but assuming oxygen on irregular basis as needed
(AN), and to normal reference values.
Methods
The participants enrolled in the present study were pa-
tients suffering from hypoxic or hypoxemic/hypercapnic
COPD as defined in the GOLD guidelines [23]. Half pa-
tients were managed according to a regular program of
home LTOT, while the remaining 50% of subjects used
only oxygen as needed, without any predefined protocol,
and in the vast majority of cases it was due to their adam-
ant refusal of LTOT.
Each patient was assessed for: lung function (complete
spirometry using CPFS/D – Medical Graphics Co.; Oak
Grove Parkway, St. Paul, Minnesota, USA); arterial
blood gases (using the ABL 735 Analyzer, Radiometer,
Copenhagen, DK); health status (using the COPD Assess-
ment test [CAT] questionnaire) [24,25]; and disability
(using the Medical Research Council [MRC] dyspnoea
scale) [26]. The prevalence of comorbidities was also
assessed in all patients by means of Charlson morbidity
index (C.M.I.) [27], together with their smoking history.Cognition was evaluated in each patient by means of
four validated psychometric questionnaires focusing dif-
ferent cognitive domains and characterized by different
sensitivity. They were sequentially administered to all
patients [22]: (1) the Mini Mental Status test (MMSE),
which assesses spatial and time orientation, attention
and calculation skills (normal score: ≥ 27 points; moder-
ate cognitive impairment: 24–18 points; severe cognitive
impairment: < 18 points [28], (2) the Clock Drawning test,
which assesses memory, attention and symbolic representa-
tion (normal score: 7–10 points; limit for cognitive impair-
ment: ≤ 6 points) [29,30]; (3) the Trial Making test (TMT)
A, which assesses visual processing and reproduction of nu-
meric sequences (limit for cognitive impairment: ≥ 94 sec)
[29,30]; (4) the TMT B, which assesses cognition flexi-
bility and shifting capacity (limit for cognitive impair-
ment: ≥ 283 sec) [30].
Psychometric data obtained from normal age-matched
controls were used as reference values [21].
Written informed consent was obtained from all
subjects participating in the study (n. study approval
3898/2011).
Statistics
All data were expressed as means ± SD (standard devi-
ation). Comparisons between groups were carried out by
means of t test. Data of both groups were also compared
to normal reference values by means of ANOVA (Duncan
test). A p < 0.05 was accepted as the lowest limit of statis-
tical significance.
Results
The total sample consists of 146 subjects (males n = 96;
66%; mean age = 70.5 ± 12.9 years ) suffering from hyp-
oxemic (and/or hypercapnic) COPD. Seventy-three pa-
tients (males n = 49, 67.1%; mean age = 71.2 ± 9.1) were
managed according to a strict protocol of regular home
LTOT with liquid oxygen for 2.9 years ± 0,9, with a
mean oxygen use of 1.7 L/min ± 0.6, for > 15 hours/day,
whereas the remaining 73 patients (males n = 48; 65.7%%;
mean age = 70.9 ± 8.9 years) used oxygen only as needed,
on irregular basis.
The general characteristics of both groups are reported
in Table 1. The two groups proved well matched regard-
ing age, gender, smoking history, BMI, dyspnoea score,
arterial blood gases, and lung function (all t test com-
parisons p < 0.05). Also the mean C.M.I. was absolutely
comparable in the two groups, being cardiovascular and
metabolic comorbidities the most represented (such as
67.4%) and equally prevailing in both groups.
The prevalence of severe cognitive impairment assessed
in the two groups is reported in Figure 1. LTOT patients
showed a significant lower prevalence of severe cogni-
tive deterioration, independently of the psychometric
Table 1 General characteristics of patients at baseline
(means ± SD) and their statistical comparison (t test)
without LTOT (n = 73) with LTOT (n = 73) p
age (ys) 70.9 ± 8.9 71.2 ± 9.1 ns
FEV1 % pred. 40.2 ± 10.3 41.6 ± 11.1 ns
FEV1/FVC 437 ± 9.2 44.2 ± 10.2 ns
BMI 27.5 ± 5.1 27.9 ± 6.4 ns
Active smokers 9.6%* 6.8%* ns
Former smokers 69.9%* 72.6%* ns
PaO2 (mmHg) 53.3 ± 7.9 54.2 ± 8.3 ns
PaCO2 (mmHg) 45.8 ± 9.9 46.1 ± 10.2 ns
CAT score 19.9 ± 4.9 18.8 ± 5,6 ns
MRC scale 2.8 ± 0.7 2.7 ± 0.8 ns
C.M.I. 4.2 ± 2.0 4.3 ± 1.9 ns
*Smoking history is indicated in % active or former smokers.
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all domains of cognition were significantly more deteri-
orated in AN patients.
Also the absolute extent of cognitive dysfunction was
measured in both groups of patients, and corresponding
data are reported in Table 2, together with the signifi-
cance level of their statistical comparison. In particular,
while the Clock test and the MMSE scores were equally
informative in the two groups, the TMT-A and the
TMT-B scores proved significantly different, and LTOT
patients resulted significantly less impaired in their cogni-
tion compared to AN patients (p < 0.012 and p < 0.001,
respectively) (Table 2).
TMT-A and TMT-B proved the most discriminant
psychometric tools and those worth of further analysis.
Currently, as normal reference values for subjects aged
40–79 years are only available in the literature for the
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Figure 1 The prevalence of severe cognition impairment in the two groupobtained in the present study (range of age 65–75 years)
were compared to corresponding normal reference values
(Figures 2 and 3).
When compared to normals, the extent of cognitive
dysfunction was significantly higher in all patients when
assessed by TMT- A and TMT-B (ANOVA p < 0.001 for
both comparisons). Nevertheless, LTOT patients proved
significantly less limited in their cognition than AN pa-
tients (t test p < 0.022 and p < 0.05, respectively).
Discussion
It is increasingly accepted that COPD is an inflammatory
multicomponent, pathological condition which can affect
several functions of different organs. Cognition represents
one of these aspects, even if little attention has been paid
to the effects of COPD on cognition in clinical practice,
particularly in the presence of hypoxemia.
In general, the occurrence of significant limitations in
cognitive functions was found to be associated with se-
vere pulmonary dysfunction, particularly when chronic-
ally persisting, as in the case of COPD [12-15]. Recently,
a specific study focused on these aspects and confirmed
that both the prevalence and the extent of cognitive de-
terioration occurring in subjects with stable COPD of
different severity are directly related to the severity of
their pulmonary condition, hypoxemia included. In these
cases, several domains of cognition are involved, and
then several functions can be deteriorated, even substan-
tially [22].
Hypoxemia has long been described as able to affect
memory [21], even if this condition has been recently
regarded as unlikely to account per se for the cognitive
dysfunction in COPD [9]. On the other hand, its crucial
role has been emphasized by other investigations which
recently proved that the chronic persistence of hypoxemia
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Figure 3 Extent of cognition impairment measured by the TMT-B
test in patients with and without LTOT, and in normal subjects (all
aged 65–75 ys) (t test between groups and ANOVA among groups).
Table 2 Extent (mean ± SD) of cognition impairment
assessed in the two groups and significance of their
comparison (t test)
test LTOT (n = 73) NO LTOT (n = 73) p
Clock test < 6 4.2 ± 1.7 3.9 ± 1.9 ns
MMSE < 24 20.1 ± 3.1 22.0 ± 2.3 ns
TMT-A > 94 132.2 ± 35.8 155.3 ± 52.5 0.012
TMT-B > 283 322.1 ± 36.2 344.2 ± 31.8 0.001
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Assessment [31]. Moreover, perception, attention, and
short term memory has been described as significantly im-
paired in hypoxemic COPD patients in stable conditions,
and the cause of this cognitive impairment has been re-
lated to neurophysiological events, such as the sustained
presence of a decreased prefrontal cortex circulation [32].
Furthermore, also the intermittent, even if persistently
occurring, hypoxemia which characterizes the obstruct-
ive sleep apnea syndrome (OSAS) has been suggested to
have a role in developing cognitive impairment at vari-
able degrees, particularly in ageing population (i.e. atten-
tion, episodic memory, working memory) [33].
When compared to corresponding normal reference
values, a substantial deterioration in cognition was assessed
in all COPD patients in present study, but according to a
peculiar pattern. In particular, some cognitive functions re-
sulted only mildly-moderately impaired (such as, those
assessed by MMSE and Clock test), while others (such as,
those assessed by TMT-A and TMT-B) resulted much
more deteriorated. It would then be surmised that sev-
eral domains of cognition are variably affected by per-
sistent hypoxemia in COPD patients, such as: memory,
attention, symbolic representation and visual processing,
reproduction of numeric sequences, cognition flexibility,
and shifting capacity. Long-term oxygen is presumed to
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Figure 2 Extent of cognition impairment measured by the TMT-A
test in patients with and without LTOT, and in normal subjects (all
aged 65–75 ys) (t test between groups and ANOVA among groups).functions. Some of them (i.e. memory and attention)
might be improved independently of the duration of
oxygen assumption, while others (such as: visual pro-
cessing, reproduction of numeric sequences, cognition
flexibility, and shifting capacity), that likely are the most
complex functions in neuro-psychological terms, are
only sensitive to long-term oxygen treatment.
Consequently, a large panel of investigational instru-
ments, covering a wide range of cognitive domains and
differently sensitive is needed in order to specify the psy-
cometric profile of these patients. Likely this is the rea-
son why the occurrence of cognitive dysfunction was
usually regarded as variable and depending on the psy-
chometric test used [34,35].
This particular aspect is also crucial when comparing
the effect of different strategies of oxygen treatment
(such as: regular OTLT vs oxygen as needed) on cogni-
tive dysfunction. In the present study, the commonly
used MMSE and Clock Drawing Test failed to discrimin-
ate the effects of home LTOT on cognition from those
of oxygen as needed. Only TMT-A and TMT-B showed
that long-term oxygen was much more effective in pre-
serving these patients from cognitive dysfunctions, even
if they still remain substantially limited compared to nor-
mal individuals. Consequently, different instruments pro-
vided with specific sensitivities should be used in order to
highlight and differentiate the pattern of response to oxy-
gen treatment.
The hypothesis that hypoxemia-induced cognitive de-
terioration might depend on complex neuro-physiological
mechanisms in COPD (i.e. systemic inflammation and
vascular damage affecting brain performance) seems to be
confirmed by a study carried out according to a multipara-
metrical approach (such as by means of Short Test of
Mental Status, transcranial Doppler ultrasonography, five
cardiovascular tests, and a questionnaire of autonomic
Figure 4 Deterioration of cognition in Chronic Obstructive Airway Disease: a comprehensive vision of the oxygen role in modulating the
pathways of cognitive dysfunction.
Dal Negro et al. Multidisciplinary Respiratory Medicine  (2015) 10:17 Page 5 of 6function) in a small sample of hypoxemic COPD patients
[36]. Also the effect of a three-month LTOT on the func-
tion of central and autonomic nervous system was investi-
gated in this study. Patients’ cognition was shown to
improve proportionally to the amelioration of their neuro-
logical parameters, cerebral blood flow velocity, and auto-
nomic function following LTOT, thus emphasizing the
reversibility (at least partial) of the COPD-induced cogni-
tive deterioration and the therapeutic effect of long-term
oxygen from this point of view.
Persistent inflammation underlies chronic airflow limi-
tation and is maximally effective in the severest condi-
tions. As cognitive deterioration has been proved to be
related to hypoxemia and to severity of airway obstruc-
tion [22], the active role of chronic inflammation in sus-
taining cognitive dysfunction can also be suggested in
COPD. A comprehensive vision of the role of hypoxemia
and of oxygen supplementation in modulating the path-
ways of cognitive dysfunction is reported in Figure 4.
In clinical terms, the strong evidence that cognition may
be significantly deteriorated in hypoxemic COPD subjects
contributes to explain why these subjects frequently dem-
onstrate an insufficient self management and their adher-
ence to therapeutic strategies frequently results inadequate.
The psychometric profile of these subjects, as shown in the
present study, can also contribute to explain their frequentrequests for admission to health institutions and the conse-
quent high economic impact.
Conclusions
In conclusion, focusing the effect of COPD on cognition
is a relevant issue for all COPD patients, independently
of their severity. The assumption that hypoxemic COPD
subjects have a substantial cognitive dysfunction mainly
affecting peculiar aspects of cognition is of strategic value
for those COPD patients who are prescribed long-term
oxygen because they frequently are not aware of the sys-
temic risks related to their condition. They should be
increasingly encouraged to accept LTOT, when needed,
because this therapeutic strategy is effective in preserving
their cognitive function from the deterioration induced by
their chronic respiratory limitations, and in preventing
progression of cognitive dysfunction.
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